Based on these evidences, we demonstrated that the NAFLD metabolic microenvironment promoted EGFR palmitoylation and that this protein lipid modification might promote its localization in PM and evasion from lysosomal degradation. This evidence concerns the gene EGFR and metabolic dysfunction-associated steatotic liver disease.